Email Address
Please enter your official email address
We notice that your permissions preference cookie is missing. Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. Receiving permission from our users is an important part of our compliance with international privacy regulations. Your email address will not be shared without your permission. Please refer to our
privacy policy
for information on how we protect your personal information.
Welcome to AdisInsight
We need some information from you before you start using the platform.
This information will allow us to better understand how AdisInsight is being used.
It does not require or replace the individual login accounts that many of you use to save searches and create email alerts.
Protecting your personal information is important.
That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight.
For further information on how we protect and process your personal information, please refer to our
privacy policy.
Terms of Service
By accessing or using the AdisInsight platform you agree to the terms of use.
Please select terms of use
How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform.
The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address.
You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. If you opt-out your email will still be collected for registration purposes.
Please choose your email permissions
Get more from AdisInsight
Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. Unsubscription is always possible via email.
Please choose your permissions
Mandatory field
Please enter your official email address
Trans sodium crocetinate - Diffusion Pharmaceuticals
Trans sodium crocetinate - Diffusion Pharmaceuticals
Alternative Names:
Crocetin sodium salt; Sodium crocetinate; Trans sodium crocetinate; Transcrocetinate sodium; TSC; TSC-cpd
Latest Information Update: 09 Jul 2020
Price :
$50
*
Adis is an information provider.
We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.
At a glance
Originator
Office of Naval Research; University of Virginia
Developer
Diffusion Pharmaceuticals; University of Virginia
Class
Antineoplastics; Carotenoids; Dicarboxylic acids; Neuroprotectants; Radiation-sensitising agents; Small molecules; Vascular disorder therapies
Mechanism of Action
Oxygen compound modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Yes
-
Brain metastases; Glioblastoma
New Molecular Entity
Yes
Available For Licensing
Yes - Glioblastoma
Highest Development Phases
Phase III
Glioblastoma
Phase II
Stroke
Phase I
Brain metastases; Pancreatic cancer
Research
Adult respiratory distress syndrome
Discontinued
Peripheral arterial disorders
Most Recent Events
07 Jul 2020
Diffusion Pharmaceuticals files an IND application for a phase I/IIb trial with the US FDA for Adult respiratory distress syndrome and Hypoxaemia
07 Jul 2020
Diffusion Pharmaceuticals plans a phase I/IIb trial in Adult respiratory distress syndrome and Hypoxaemia (associated with COVID-2019) in Romania and USA in July 2020
11 Jun 2020
Diffusion Pharmaceuticals plans to submit an IND application with the US FDA for a clinical trial in Adult respiratory distress syndrome associated with COVID-2019 infections in June 2020, with expected accelerated response
Restricted Access
If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at
AsktheExpert.AdisInsight@springer.com
to find out more. Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.
Login
with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
